VIDEO: Wilson discusses PROTECTED TAVR, CLASP IID trials and more from TCT 2022

ByErik Swain

ByScott Buzby

ByB. Hadley Wilson, MD, FACC

Add topic to email alerts

Please provide your email address to receive an email when new articles are posted on Pediatric Emerging Diseases.

BOSTON — In this Healio video exclusive, B. Hadley Wilson, MD, FACC, discussed late-breaking research in transcatheter aortic valve replacement, and more presented at TCT 2022.

Wilson, who is executive vice chair of Atrium Health’s Sanger Heart and Vascular Institute and clinical professor of medicine at UNC School of Medicine, provided his perspective on the PROTECTED TAVR and CLASP IID trials as well as findings from analyses of the TVT and U.K. National Registries.

Watch the video for more.

References:

Alkhouli M, et al. Late-Breaking Clinical Science in Structural Heart Disease: Session I, in Collaboration With The New England Journal of Medicine. Presented at: TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).
Giblett J, et al. Late-Breaking Science in Structural Heart Disease: Session II, in Collaboration With The European Heart Journal/EuroIntervention. Presented at: TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).
Kapadia SR, et al. Late-Breaking Clinical Science in Structural Heart Disease: Session I, in Collaboration with The New England Journal of Medicine. Presented at: TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).
Kapadia SR, et al. N Engl J Med. 2022;doi:10.1056/NEJMoa2204961.
Koulogiannis KP, et al. Late-Breaking Clinical Science in Structural Heart Disease: Session I, in Collaboration With The New England Journal of Medicine. Presented at: TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).
Lim DS, et al. JACC Cardiovasc Interv. 2022;doi:10.1016/j.jcin.2022.09.005.
Simard T, et al. J Am Coll Cardiol. 2022;doi:10.1016/j.jacc.2022.09.006.